MedTrace Logo

Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+

NCT01354457 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2014-06-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether fractionated RIT with Epratuzumab and radiolabeled Epratuzumab are effective in the treatment of relapsing or refractory ALL.

Conditions

Interventions

DRUG

Epratuzumab and 90Y-Epratuzumab

Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Chevallier Patrice, MD · Nantes University Hospital

  • Kraeber-Bodere Françoise, MD · Nantes University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354457 on ClinicalTrials.gov